Is CohBar, Inc. (CWBR) a Buy, Sell, or Hold?
NASDAQ : CWBR
CohBar, Inc.
$0.41 USD
$0 (0.0%)
- Volume
- 172
- Average Volume
- 3.04K
- Market Capitalization
- $1.19M
- P/E Ratio
- -0.10
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.01
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.69
Company Overview
NASDAQ
Pinchas Cohen Dean,
Biotechnology
Healthcare
CWBR
9
US
USD
Liquidity Metrics
0.00
15.69
15.69
5.74
0.00
Sales & Valuation
-$
0.00
0.08
-0.11
-3.60
Profitability
-$4.12
-$11.96M
0.00%
0.00%
-58.44%
-73.09%
P/E Metrics
-0.10
-0.03
-0.03
Analyst Price Target & Rating
0/5
5 Analysts
%
Financial Health Scores
-13.78
1/9
$9.47M
$12.51M
$3M
-$12.69M
Key Metrics (TTM)
-$4.74M
0.00
0.39
15.69
-58.44%
-79.39%
-1006.76%
-876.50%
0 days
Company Executives
| Name | Title |
|---|---|
| Pinchas Cohen Dean | Co-Founder & Member of Scientific Advisory Board |
| Nir Yacov Barzilai | Co-Founder & Member of Scientific Advisory Board |
| John Amatruda | Co-Founder |
| Jordyn Tarazi | Director of Investor Relations |
Poll Results
No votes yet today — be the first to share your view!
About CohBar, Inc. (NASDAQ:CWBR) Stock
CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as ... part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Frequently Asked Questions
-
What is the current CohBar, Inc. (CWBR) stock price?
-
CohBar, Inc.(NASDAQ:CWBR) stock price is $0.41 in the last trading session. During the trading session, CWBR stock reached the peak price of $1.01 while $0.0011 was the lowest point it dropped to. The percentage change in CWBR stock occurred in the recent session was 0.0% while the dollar amount for the price change in CWBR stock was $0.
-
CWBR's industry and sector of operation?
-
The NASDAQ listed CWBR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CWBR?
-
Pinchas Cohen Dean | Co-Founder & Member of Scientific Advisory Board
Nir Yacov Barzilai | Co-Founder & Member of Scientific Advisory Board
John Amatruda | Co-Founder
Jordyn Tarazi | Director of Investor Relations
| -
How many employees does CWBR have?
-
Number of CWBR employees currently stands at 9. CWBR operates from 1455 Adams Drive, Menlo Park, CA 94025, US.
-
Link for CWBR official website?
-
Official Website of CWBR is: https://www.cohbar.com
-
How do I contact CWBR?
-
CWBR could be contacted at phone #650 446 7888 and can also be accessed through its website. CWBR operates from 1455 Adams Drive, Menlo Park, CA 94025, US.
-
How many shares of CWBR are traded daily?
-
The average number of CWBR shares traded daily for last 3 months was 3.04K.
-
What is the market cap of CWBR currently?
-
The market value of CWBR currently stands at $1.19M with its latest stock price at $0.41